J Liver Cancer Search

CLOSE


J Liver Cancer > Volume 16(2); 2016 > Article
Journal of Liver Cancer 2016;16(2):134-138.
DOI: https://doi.org/10.17998/jlc.16.2.134    Published online September 30, 2016.
A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Invasion that Showed Favorable Prognosis after Combined External Radiation Therapy and Sorafenib Therapy
Namyoung Paik1, Dong Hyun Sinn1, Hee Chul Park2, Woo Kyung Jeong3, Min Sun Kim1, Ji Hye Kim1, Bumhee Yang1
1Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea
2Departments of Radio-oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea
3Departments of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea
Correspondence:  Dong Hyun Sinn,
Email: dh.sinn@samsung.com
Copyright ©2016 by The Korean Liver Cancer Association
Abstract
A prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal that the median survival is 2 to 4 months without treatment. Sorafenib, the standard regimen of advanced HCC, can prolong median survival only 1.5 months. A 50-year-old man with a history of chronic hepatitis B was diagnosed advanced HCC with PVTT. By a multidisciplinary medical team approach, the combination of 3-demensional conformal radiation therapy with sequential sorafenib was challenged. 4 months after initiation of treatment, he achieved partial response as modified response evaluation criteria in solid tumors criteria. Sorafenib was continued so far, and stable disease has been maintained up to now, without significant adverse effect.
Key Words: Hepatocellular carcinoma; Sorafenib; Radiation therapy
NULL


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next